The 2026 ASC valuation gap: single centers fetch 5x-8x, platforms 11x-17x

For an ambulatory surgery center owner thinking about a sale, a recapitalization, or selling a syndication stake, one number settles the conversation: the EBITDA multiple. It is the figure that converts a center’s annual earnings into a transaction price. And in 2026, the multiple a center commands depends less on how well it runs than on what it is — a single specialty, a diversified center, or part of a platform.

Two 2026 sources frame the range. FOCUS Investment Bankers, in its Ambulatory Surgery Center EBITDA Multiples report published April 3, 2026, lays out current benchmark bands. VMG Health, in its 2026 guide to selling an ASC, describes where most individual centers land. Read together, they tell an owner whether to sell now, scale first, or hold.

What the multiple measures

A multiple is shorthand for risk-adjusted earnings durability. Apply a multiple to a center’s EBITDA and you get its enterprise value; the same earnings fetch a different price depending on how secure a buyer judges those earnings to be. That is why the same dollar of EBITDA is worth more inside a 12-center regional operator than inside a standalone two-surgeon center — the buyer is pricing the stability of the earnings, not just their size.

VMG Health’s selling guide puts the standalone case plainly, describing many centers as trading around the historical benchmark of 7-8x EBITDA. That sits at the upper end of the 5x-8x range FOCUS publishes for single-specialty centers — a useful sanity check for any owner whose banker is quoting a number well outside it.

The single-center-to-platform spread

The FOCUS benchmarks separate cleanly by structure. Single-specialty ASCs run roughly 5x-8x EBITDA, multispecialty centers 6x-10x, and regional ASC operators or management companies 11x-17x. The top of the platform band is more than double the top of the single-center band — the clearest signal in the data that aggregation, not operations, is what re-rates a center.

FOCUS is explicit about why diversification pays. “Multi-specialty facilities generally command higher multiples because they diversify procedure revenue and reduce reliance on a single physician group or surgical discipline,” the report states. Single-specialty centers are not penalized outright — FOCUS notes they “can still achieve strong valuations when the specialty is particularly profitable or in high demand” — but they “carry higher concentration risk.” That risk is the discount.

The drivers buyers actually price

Beneath the structure bands, FOCUS names the inputs that move a center within its range. Physician concentration is first: facilities that “rely heavily on one or two surgeons for case volume face higher risk, which can reduce valuation multiples,” while centers with “a broad physician ownership base and stable referral patterns typically achieve stronger pricing.” For a single-specialty center, surgeon concentration is both the source of its profitability and the cap on its multiple.

Payer mix is the second lever, and it cuts against a model some centers have leaned on. FOCUS warns that “high levels of out-of-network revenue can introduce uncertainty about the durability of reimbursement rates,” and that “investors may discount valuations for centers that depend heavily on out-of-network billing models.” An owner counting out-of-network upside as a selling point may find a buyer counting it as a risk.

Control is its own multiple

Structure is not only about specialty mix — it is about who holds the keys. FOCUS prices governance directly: non-controlling physician interests trade at roughly 3x-6x EBITDA, because “minority interests typically trade at lower multiples because they lack governance control and management authority.” Controlling buyers acquiring majority stakes, by contrast, “may pay 6x-8x EBITDA or higher, depending on the quality of the center.”

For a physician syndicate, that gap reframes the sale decision. A minority stake sold into a third party fetches the 3x-6x band; the same earnings sold as a control position to a platform buyer can command the higher figure. The structure of the stake — not just the center — sets the number.

The sell-vs-scale calculus

Put the bands together and the strategic question is concrete. A single-specialty owner sitting at, say, 7x has two visible paths to a higher exit multiple. One is to diversify into a multispecialty footprint, moving into the 6x-10x band on the strength of revenue that no longer rides on one discipline. The other is to join or build toward a platform, where regional and national operators clear 11x-17x — the territory that has drawn private-equity-backed roll-ups into the sector.

Neither path is free. Diversification means adding service lines, surgeons, and capital before the re-rating arrives; platform scale means ceding some control, which is its own form of price. And the bands are benchmarks, not quotes — the multiple any individual center commands turns on its own physician base, payer mix, case mix, and local market, the exact inputs FOCUS flags. The value of these benchmarks is directional: they tell an owner roughly how much a structural change is worth, so the cost of getting there can be weighed against it.

What to watch

The bands themselves move with the rate environment underneath them, so the policy calendar matters to the valuation calendar. The CY2027 OPPS/ASC proposed rule, expected around July on the annual cycle, will reset the payment trend that buyers capitalize into every multiple. FOCUS updates its healthcare EBITDA benchmarks periodically, so a future read will show whether the platform premium is widening or compressing. And as 2026 deal season runs its course, the spread between the single-center bands and the 11x-17x platform range is the figure to track: it is the running price of scale, and the clearest measure of whether the sector’s aggregation thesis still holds.